# Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Re

Source: https://onco.cc/trials/nct07225270/  
OnCo record `nct07225270` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Rinatabart sesutecan, Bevacizumab in ovarian cancer, run by Genmab, now recruiting.

## Summary

Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy is a phase 3 interventional study registered as NCT07225270 by Genmab, with 544 participants planned, started 2026-04-03 and due to reach its primary completion in 2028-10. Interventions recorded: Rina-S, Bevacizumab. Conditions listed: Ovarian Cancer, Platinum-sensitive Ovarian Cancer, PSOC. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07225270
- Phase: 3
- Setting: A Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Versus Standard of Care as Maintenance Treatment After 2L Platinum-Based Doublet Chemotherapy in Participants With Recurrent Platinum-Sensitive Ovarian Cancer (PSOC)
- Sponsor: Genmab
- Enrolled: 544

## Sources

- ClinicalTrials.gov NCT07225270: https://clinicaltrials.gov/study/NCT07225270

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Rinatabart sesutecan](https://onco.cc/drugs/rinatabart-sesutecan/)
- companies: [Genmab](https://onco.cc/companies/genmab/)

---
JSON: https://onco.cc/api/v1/entities/nct07225270.json